Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 5/20 | 0.40 |
| ▸ | AMY2A | P04746 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 4/20 | 0.34 |
| ▸ | SI | P14410 | 4/20 | 0.34 |
| ▸ | FGF1 | P05230 | 2/20 | 0.34 |
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14930086 | 0.89 | LGALS8 (0.35) | LGALS8AMY2AMGAMSIFGF1 | |
| SCHEMBL14925561 | 0.89 | LGALS8 (0.38) | LGALS8AMY2AMGAMSIFGF1 | |
| SCHEMBL14925562 | 0.88 | GJB2 (0.35) | LGALS8AMY2AFGF1G6PD | |
| SCHEMBL16442179 | 0.87 | LGALS8 (0.35) | LGALS8FGF1MEN1KMT2A | |
| SCHEMBL14925559 | 0.86 | GJB2 (0.39) | LGALS8AMY2AFGF1 | |
| SCHEMBL16442174 | 0.84 | LGALS8 (0.36) | LGALS8AMY2AFGF1G6PD | |
| SCHEMBL12219328 | 0.81 | LGALS8 (0.38) | LGALS8MGAMSIG6PDGAA | |
| SCHEMBL19213281 | 0.81 | LGALS8 (0.38) | LGALS8MGAMSIG6PDGAA | |
| SCHEMBL7538441 | 0.79 | SSTR1 (0.47) | LGALS8MEN1KMT2A | |
| SCHEMBL7150857 | 0.79 | LGALS8 (0.40) | LGALS8AMY2AMGAMSIFGF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116331-A1 | MEDICAL GEL | BRUSELLS VENTURES CORP. (VG) | 2013-05-09 | — | — | US | disclosed |
| US-20130116331-A1 | MEDICAL GEL | BRUSELLS VENTURES CORP. (VG) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116331-A1 | MEDICAL GEL | CUTA, SHH, POLR1C | LGALS8 3824/4885AMY2A 3385/4885MGAM 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.